CardiNor
Pre-clinicalIC Targets AS (ICT) has acquired a 92 % stake in CardiNor AS, a Norwegian diagnostics company committed to combating the heart failure (HF) epidemic through its patented blood biomarker, secretoneurin (SN). We see strong synergies between the two companies’ diagnostic solutions for heart failure: CardiNor’s low-cost SN blood test and the proprietary MRI contrast agent mangafodipir from ICT. Elevated SN levels are a strong indicator that cardiac MRI should be performed to assess for structural...
About
IC Targets AS (ICT) has acquired a 92 % stake in CardiNor AS, a Norwegian diagnostics company committed to combating the heart failure (HF) epidemic through its patented blood biomarker, secretoneurin (SN). We see strong synergies between the two companies’ diagnostic solutions for heart failure: CardiNor’s low-cost SN blood test and the proprietary MRI contrast agent mangafodipir from ICT. Elevated SN levels are a strong indicator that cardiac MRI should be performed to assess for structural...
Funding History
2Total raised: $10M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile